Clinical benefit of paclitaxel/carboplatin plus bevacizumab with zoledronic acid in pulmonary epithelioid hemangioendothelioma complicated by hypertrophic pulmonary osteoarthropathy and cardiac tamponade: a case report - Top-Institutions - MDSpire

Clinical benefit of paclitaxel/carboplatin plus bevacizumab with zoledronic acid in pulmonary epithelioid hemangioendothelioma complicated by hypertrophic pulmonary osteoarthropathy and cardiac tamponade: a case report

  • By

  • Saki Tsuchimochi

  • Hiromichi Nakajima

  • Yukako Hattori

  • Shioto Oda

  • Hiroki Imada

  • Tetsuro Taki

  • Anna Matsuoka

  • Shogo Watanabe

  • Akira Hirota

  • Mai Shimura

  • Misao Fukuda

  • Chikako Funasaka

  • Kenichi Harano

  • Nobuaki Matsubara

  • Yoichi Naito

  • Ako Hosono

  • Genichiro Ishii

  • Toru Mukohara

  • June 2, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Gynecologic Oncology Group
    Gynecologic Oncology Group

    Kiel, Germany

    Key Differentiators

    • Gynecologic Oncology

  • #2

    local hospital
    local hospital

    Unknown, Unknown

    Key Differentiators

    • General Healthcare

  • #3

    our hospital
    our hospital

    Unknown, Unknown

    Key Differentiators

    • General Healthcare

  • #4

    University of Milan-Bicocca
    University of Milan-Bicocca

    Milan, Italy

    Key Differentiators

    • Oncology

  • #5

    European Institute of Oncology
    European Institute of Oncology

    Milan, Italy

    Key Differentiators

    • Oncology

Original Source(s)

Clinical benefit of paclitaxel/carboplatin plus bevacizumab with zoledronic acid in pulmonary epithelioid hemangioendothelioma complicated by hypertrophic pulmonary osteoarthropathy and cardiac tamponade: a case report

  • by Saki Tsuchimochi, Hiromichi Nakajima, Yukako Hattori, Shioto Oda, Hiroki Imada, Tetsuro Taki, Anna Matsuoka, Shogo Watanabe, Akira Hirota, Mai Shimura, Misao Fukuda, Chikako Funasaka, Kenichi Harano, Nobuaki Matsubara, Yoichi Naito, Ako Hosono, Genichiro Ishii, Toru Mukohara

  • June 2, 2026

Related Content

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy

Signals of inequity in the care pathway: rural lab diagnosis, systemic therapy delays, and RAS mutation differences in metastatic colorectal cancer

Target receptor expression dictates the selective intra-tumoral targeting of CD8+ T cells by eciskafusp alfa in matched PBMCs and TILs from CPI-naïve patients